Drug Profile
Imiglucerase biosimilar - ISU Abxis
Alternative Names: Abcertin; ISU-302Latest Information Update: 28 Mar 2023
Price :
$50
*
At a glance
- Originator ISU Abxis
- Class Glucosidases
- Mechanism of Action Glucosylceramidase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Gaucher's disease
Most Recent Events
- 28 Mar 2023 No recent reports of development identified for phase-I development in Gaucher's-disease(In volunteers) in Australia (IV, Infusion)
- 09 Jul 2020 ISU Abxis completes a phase I trial in Gaucher's disease (In volunteers) in Australia (IV) (ACTRN12619001399189)
- 17 Oct 2019 ISU Abxis plans a phase I trial in healthy volunteers in Australia (IV) (ACTRN12619001399189p)